About ESLHO
The European Scientific foundation for Laboratory Hemato Oncology (ESLHO) is a scientifically independent foundation that promotes innovation, standardization, quality control and education of laboratory diagnostics focused on lymphoid malignancies, together with the associated consortia EuroClonality, EuroFlow and EuroMRD.
ESLHO Symposium
Every year in November, ESLHO organizes a scientific symposium. During this event, speakers from all over the world share their knowledge and talk about the latest results from research projects related to laboratory diagnostics for lymphoid malignancies.
EU Regulation on in vitro diagnostic medical devices (IVDR)
The IVDR, which will regulate all in vitro diagnostic medical devices (IVDs) from May 2022 onwards, will have a major impact on IVD manufacturers as well as diagnostic laboratories. To aid laboratories from the ESLHO networks with their preparations for the IVDR, including compliance to the IVDR requirements for in-house devices, ESLHO provides information and support in the form of lectures, symposia, publications and a dedicated web page.
EHA-SWG
ESLHO is a Specialized Working Group of the European Hematology Association. At the annual EHA Congress, ESLHO presents its innovations in the special EHA-SWG sessions.
News
Open ESLHO Symposium on November 7th in Lisbon
2024-05-08
ESLHO organizes the 13th ESLHO Symposium on the 7th of November in LIsbon, Portugal. At the Convento do Beato, speakers from all over the world will share their knowledge on Multi-omics approaches for diagnosis and monitoring of hematological malignancies. Participants of the 13th ESLHO Symposium will be provided with the latest updates on the development and use of multi-omics approaches for the diagnosis and monitoring of hematological malignancies.
EQA Schemes opened for registration
2024-01-18
External Quality Assessment schemes are a tool for clinical laboratories to evaluate and manage the quality of laboratory practice with the support of an independent party.
The ESLHO EQA schemes help diagnostic laboratories worldwide to achieve the highest performance and quality. IG/TR clonality testing, MRD and flow cytometric immunophenotyping have become essential for an accurate diagnosis, classification, and disease monitoring in hemato-oncology. The EQA schemes answer the need for evaluation of performance, continuous improvement and education, and standardization/comparability of measurements in different diagnostic centers for these In Vitro Diagnostic tests.
Registration for the 2024 rounds of the EQA schemes of EuroClonality, EuroMRD and EuroFlow is now open. Do you wish to participate or want to learn more? Go to: eqascheme.org (IG/TR Clonality), www.euromrd.org (MRD) and/or www.euroflow.org/qa (FLOW) 📷 credit: Biomedical Quality Assurance Research Unit of the KU Leuven.
ESLHO Symposium in Salamanca well-attended
2023-12-06
The annual ESLHO week took place from 5 to 12 November. In the beautiful historic city of Salamanca, Spain, participants from all three ESLHO consortia, EuroFlow, EuroClonality and EuroMRD, came to the Hospedaria Fonseca to present and discuss the status and results of their joint scientific research and EQA programs. The highlight of the week was the 12th ESLHO Symposium titled 'New Developments in flow cytometry, immunogenetics and MRD assessment', with speakers from all over the world. During the day there was a special Poster Session where visitors could stay informed of the latest developments of the laboratories involved and the entrants could win the Special Poster Prize. This year's winner was Kerry Wall with her poster entitled: ‘Molecular residual disease analysis in a high throughput laboratory setting: Can automated DNA extraction of total white blood cells effectively substitute for DNA obtained via mononuclear cell separation?’